Psoriatic Arthritis - KOL Insight

Description

What clinical and commercial factors are influencing KOLs' prescribing decisions for Novartis' Cosentyx and Lilly's Taltz anti-IL-17 therapies? In the IL-23 inhibitor sector, how do rheumatologists assess the clinical advantages of Janssen's Tremfya and AbbVie/Boehringer Ingelheim's Skyrizi in patients with severe skin disease who have milder arthritis or IBD? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

15 Jun 23 KOL Bulletin -- Views on the long-term Phase III data for UCB'S Bimzelx

16 Jun 23 KOL Bulletin -- Views on post-hoc analysis of Phase III COSMOS data for Janssen's Tremfya

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs

Anti-tumour necrosis factor agents
- Key insights summary
Interleukin-17 inhibitors
- Cosentyx (secukinumab; Novartis)
- Taltz (ixekizumab; Lilly)
Interleukin-12/23 and interleukin-23 inhibitors
- Stelara (ustekinumab; Janssen)
- Tremfya (guselkumab; Janssen)
- Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
Janus kinase (JAK) inhibitors
- Xeljanz (tofacitinib; Pfizer)
- Rinvoq (upadacitinib; AbbVie)
Type 4 cyclic nucleotide phosphodiesterase inhibitors
- Otezla (apremilast; Amgen)
T-cell activation inhibitors
- Orencia (abatacept; Bristol Myers Squibb)

Pipeline drugs

Interleukin-17 inhibitors
- Bimzelx (bimekizumab; UCB)
- Izokibep (Affibody/Acelyrin)
- Sonelokimab (MoonLake Immunotherapeutics)
Interleukin-23 inhibitors
- Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
Tyrosine kinase 2 (TYK2) inhibitors
- Sotyktu (deucravacitinib; Bristol Myers Squibb)
- TAK-279 (Takeda)
TYK2/JAK-1 inhibitor
- Brepocitinib (Priovant Therapeutics)
Mitogen-activated protein kinase-activated protein kinase-2 inhibitor
- Zunsemetinib (Aclaris Therapeutics)